Front Endocrinol (Lausanne) (2019) 10:83:83
Food and Drug Administration has provided regulatory guidance in the publication Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing available at: which is incorporated herein by reference in its entirety
Although human studies are still necessary to fully understand its effects and potential applications, the evidence gathered so far provides an optimistic outlook for dihexa peptide as part of a multifaceted approach to cognitive wellness
What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation
Pozniak CD, Sengupta Ghosh A, Gogineni A, Hanson JE, Lee SH, Larson JL, et al